Rezolute Inc.Redwood City, California, United States
Disclosure information not submitted.
SAT-087 - A Case Series on the Compassionate Use of Ersodetug, an Insulin Receptor Modulating Antibody, in Patients with Refractory Hypoglycemia Due to Malignant Insulin-Secreting Tumors
Saturday, June 13, 20269:30 AM - 4:30 PM CT
ORF10-06 - Ersodetug (RZ358) in Congenital Hyperinsulinism: Top-Line Results from a Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (sunRIZE)
Saturday, June 13, 20262:30 PM - 2:45 PM CT
.jpg)
.jpg)